by John Conrad | Oct 10, 2025 | Policy News
There’s been a lot of misinformation circulating about the 340B Drug Pricing Program and HB2371 in Illinois. Let’s separate fact from fiction. We’ve been hearing some wild claims from hospital lobbying groups about what will happen if HB2371 doesn’t pass....
by John Conrad | Sep 26, 2025 | Policy News
John Conrad, President and CEO of the Illinois Biotechnology Innovation Organization (iBIO) issued the following response regarding proposed 100% import duties on proprietary pharmaceutical products: “iBIO supports expanding domestic life sciences manufacturing....
by John Conrad | Aug 21, 2025 | Policy News
iBIO has joined AdvaMed and 65 other organizations in urging the Centers for Medicare and Medicaid Services (CMS) to create a streamlined pathway for Medicare patients to access FDA-authorized breakthrough medical technology. The coalition’s letter to CMS...
by John Conrad | Aug 20, 2025 | iBIO News, Policy News
The Illinois Biotechnology Innovation Organization (iBIO) delivered a coalition lettercoalition letter signed by 74 companies and organizations from across Illinois to the state’s U.S. Congressional delegation, urging immediate action to reauthorize the Small Business...
by John Conrad | Aug 4, 2025 | Policy News
Illinois companies stand to lose $90 million in annual funding if federal programs expire September 30th Illinois life sciences companies and associations have until August 15th to sign onto a group letter urging the state’s Congressional Delegation to...
by John Conrad | May 12, 2025 | Policy News
“The President’s Most Favored Nation proposal represents a catastrophic misstep for American biosciences innovation and patient access to life-saving treatments,” said John Conrad, President and CEO of the Illinois Biotechnology Innovation Organization. “This...
